Chromozym PK Activators encompass a diverse set of chemical compounds that facilitate the enhancement of Chromozym PK activity through various signaling pathways. The increase in intracellular levels of cyclic nucleotides cAMP and cGMP is a common mechanism by which these activators exert their influence. Compounds such as Forskolin, IBMX, Anagrelide, Rolipram, Cilostamide, Milrinone, and Dipyridamole raise cAMP levels by either directly activating adenylate cyclase or inhibiting phosphodiesterases, thus preventing cAMP breakdown. The resulting heightened cAMP levels activate PKA, which can phosphorylate Chromozym PK, leading to its enhanced activity. Additionally, Sildenafil, Zaprinast, Vardenafil, and Tadalafil selectively inhibit PDE5, increasing cGMP levels, which potentially leads to the activation of Chromozym PK through cGMP-dependent protein kinases. PMA, a potent activator of PKC, can also phosphorylate proteins downstream, and this pathway may intersect with Chromozym PK, thereby enhancing its activity through a phosphorylation-dependent mechanism.
The biochemical activation mechanisms of these Chromozym PK activators are crucial for understanding their role in cellular signaling. PKA and PKC are well-established kinases that phosphorylate a wide array of substrates, including Chromozym PK, suggesting that manipulation of these kinase pathways can result in the enhanced activity of Chromozym PK. Phosphodiesterase inhibitors like IBMX and Dipyridamole serve to sustain the signaling processes by preventing the degradation of cyclic nucleotides, further potentiating the activation of Chromozym PK. In contrast, PDE-specific inhibitors such as Anagrelide, Rolipram, Cilostamide, Milrinone (targeting PDE3), and Sildenafil, Zaprinast, Vardenafil, Tadalafil (targeting PDE5) provide a more targeted approach to elevating the levels of cAMP or cGMP, thus fine-tuning the pathway activation and consequential Chromozym PK activity. The interplay between cAMP and cGMP levels and their respective protein kinases forms a regulatory network that can be modulated by these compounds to ensure the functional upregulation of Chromozym PK. This network operates through the precise control of phosphorylation states, which is a fundamental mechanism for the activation of many proteins, including Chromozym PK, emphasizing the importance of these activators in cellular signaling dynamics.
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels. Elevated cAMP activates PKA, which can phosphorylate and thereby enhance the activity of Chromozym PK. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a PKC activator, which can phosphorylate downstream proteins, potentially increasing Chromozym PK activity through phosphorylation-dependent mechanism. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, which prevents cAMP degradation, potentially enhancing PKA activity and subsequent phosphorylation of Chromozym PK. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Zaprinast inhibits PDE5 and PDE6, increasing cGMP levels, which may activate cGMP-dependent protein kinases that could enhance Chromozym PK activity. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $147.00 | ||
Anagrelide inhibits PDE3, leading to increased cAMP levels, which could enhance PKA activity and thereby increase Chromozym PK phosphorylation and activation. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram selectively inhibits PDE4, leading to raised cAMP levels that could enhance PKA-mediated phosphorylation of Chromozym PK. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $90.00 $350.00 | 16 | |
Cilostamide is a selective inhibitor of PDE3, which raises cAMP levels, potentially enhancing PKA activity and Chromozym PK activation. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $162.00 $683.00 | 7 | |
Milrinone selectively inhibits PDE3, increasing cAMP levels, which could lead to enhanced PKA activity and subsequent Chromozym PK activation. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $516.00 $720.00 $16326.00 | 7 | |
Vardenafil is a PDE5 inhibitor which increases cGMP levels, potentially leading to activation of cGMP-dependent protein kinases that can enhance Chromozym PK activity. | ||||||
Tadalafil | 171596-29-5 | sc-208412 | 50 mg | $176.00 | 13 | |
Tadalafil is another selective inhibitor of PDE5, which could increase cGMP levels, leading to the activation of Chromozym PK through cGMP-dependent protein kinases. |